Unibest 优贝德
Login / Register
API (Commercialized)GMP/DMFGastroenterology / H. pylori

Vonoprazan

Reflux esophagitis, gastric ulcer; eradication of Helicobacter pylori with antibiotics

CAS No.
881681-00-1
Indication Class
Gastroenterology / Hepatology
Patent Expiry
Off-patent · 2026 (indicative)
Therapeutic Area
Gastroenterology / H. pylori
Target / Mechanism
ATP4A·ATP4B
Labeled Purity
99%+
Registration Readiness
GMP/DMF
Commercialization Tier
API (Commercialized)
Linked Intermediates
Confirm per inquiry
Patent Scope
Japan compound patent; US later
First-marketed P-CABPotent Acid SuppressionH. pylori Eradication

Key Intermediates for This API

Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher

No intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.

Listing Logic · Why It's Worth Listing

The first marketed P-CAB with stronger, more durable acid suppression and markedly higher H. pylori eradication; especially sizable demand in high-H. pylori Asian markets.

Demand

Gastroenterology / H. pylori · Marketed; available for immediate sourcing

Compliance

GMP/DMF-ready; supports regulatory filing and audit in target markets

Supply

Intermediates confirmed per inquiry

Product Description

Vonoprazan is a medication belonging to the potassium-competitive acid blocker (PCAB) class. It is used for treating stomach and duodenal ulcers as well as for eradicating Helicobacter pylori infection when used in combination with antibiotics. Unlike traditional proton-pump inhibitors (PPIs), vonoprazan does not require activation in an acidic environment. It directly and reversibly inhibits the proton pump in gastric parietal cells, leading to a more potent, rapid, and prolonged suppression of gastric acid secretion. This makes it particularly effective for conditions like erosive esophagitis and Helicobacter pylori infection.

Supply source: Unibest · Vonoprazan, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.